HC Wainwright Analysts Decrease Earnings Estimates for ATNM

Actinium Pharmaceuticals, Inc. (NYSE:ATNM) – Equities researchers at HC Wainwright reduced their FY2027 earnings per share estimates for Actinium Pharmaceuticals in a note issued to investors on Monday, October 27th. HC Wainwright analyst J. Pantginis now expects that the company will earn ($0.96) per share for the year, down from their previous forecast of ($0.89). The consensus estimate for Actinium Pharmaceuticals’ current full-year earnings is ($1.41) per share.

Actinium Pharmaceuticals Trading Down 2.7%

ATNM opened at $1.42 on Wednesday. Actinium Pharmaceuticals has a 1-year low of $1.03 and a 1-year high of $2.41. The stock’s fifty day simple moving average is $1.60 and its 200 day simple moving average is $1.57. The stock has a market cap of $44.30 million, a PE ratio of -1.02 and a beta of -0.25.

Hedge Funds Weigh In On Actinium Pharmaceuticals

A number of hedge funds have recently bought and sold shares of ATNM. Jane Street Group LLC bought a new position in shares of Actinium Pharmaceuticals during the second quarter worth approximately $306,000. Qube Research & Technologies Ltd bought a new position in Actinium Pharmaceuticals during the 2nd quarter worth $70,000. Marshall Wace LLP bought a new position in Actinium Pharmaceuticals during the 2nd quarter worth $137,000. North Star Asset Management Inc. increased its stake in Actinium Pharmaceuticals by 100.0% during the 2nd quarter. North Star Asset Management Inc. now owns 20,000 shares of the company’s stock worth $28,000 after acquiring an additional 10,000 shares during the period. Finally, Y Intercept Hong Kong Ltd bought a new position in shares of Actinium Pharmaceuticals in the second quarter worth $91,000. 27.50% of the stock is owned by institutional investors.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).